Go Pro
→ Sell Tesla, Buy the New King of FSD Cars (From Chaikin Analytics) (Ad)tc pixel
OTCMKTS:UCBJF

UCB 7/30/2026 Earnings Report

UCB logo
$307.59 0.00 (0.00%)
As of 07/2/2026 03:18 PM Eastern
ProfileForecast

UCB EPS Results

Actual EPS
N/A
Consensus EPS
$5.39
Beat/Miss
N/A
One Year Ago EPS
N/A

UCB Revenue Results

Actual Revenue
N/A
Expected Revenue
$4.55 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

UCB Announcement Details

Quarter
Date
7/30/2026
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

UCB Earnings Headlines

Belgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billion
May 3, 2026  |  reuters.comhttps://www.reuters.com/legal/transactional/belgian-pharma-group-ucb-buy-candid-therapeutics-up-22-billion-2026-05-03/
Belgian pharma UCB to buy U.S.-based Neurona for up to $1.15B
April 17, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4576267-belgian-pharma-ucb-buy-us-based-neurona
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect.tc pixel
July 6 at 1:00 AM  |  Weiss Ratings (Ad)
Belgium's UCB in autoimmune drug deal with Antengene
March 3, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/belgiums-ucb-autoimmune-drug-deal-with-antengene-2026-03-04/
Day by Day maintains UCB (UCBJF) buy recommendation
December 17, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/day-by-day-maintains-ucb-ucbjf-buy-recommendation/ar-AA1Su13Z
UCB price target raised to EUR 300 from EUR 230 at JPMorgan
December 8, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/ucb-price-target-raised-to-eur-300-from-eur-230-at-jpmorgan/ar-AA1RXfAq
See More UCB Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like UCB? Sign up for Earnings360's daily newsletter to receive timely earnings updates on UCB and other key companies, straight to your email.

About UCB

UCB (OTCMKTS:UCBJF) S.A. is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline. Notable medicines associated with UCB include Cimzia (certolizumab pegol), used in inflammatory and autoimmune conditions, and antiepileptic agents such as levetiracetam (Keppra) and brivaracetam (Briviact). UCB invests in R&D across discovery, clinical development and lifecycle management and frequently collaborates with academic groups, biotechnology partners and contract research organizations to advance novel mechanisms and delivery approaches.

Headquartered in Brussels, UCB operates internationally, serving patients and healthcare systems across Europe, North America, Asia-Pacific and other regions. The company is managed through an executive leadership team and overseen by a board of directors; it also maintains manufacturing, regulatory and commercial functions to support global product supply and market access. UCB’s strategic priorities emphasize scientific innovation, targeted therapeutic development and partnerships aimed at addressing unmet medical needs in neurology and immunology.

View UCB Profile
Earnings Tools